Premium listings
  • 3rd International Conference on Transcriptomics

    3rd International Conference on Transcriptomics

    Life Sciences Bangkok (Bangkok) March 13, 2017 Check with publisher

    Conference Series has been instrumental in conducting international Biochemistry meetings for seven years, and very excited to expand Europe, America and Asia Pacific continents. Previous meetings were held in major cities like Philadelphia, Orlando ...

  • Developing drugs for the treatment of neurodegenerative diseases

    Developing drugs for the treatment of neurodegenerative diseases

    PhD Studentships Liverpool December 3, 2016 Check with publisher

    Ageing is arguably the major biomedical challenge of the 21st century with the incidence of age-related diseases, and neurodegenerative diseases in particular, expected to increase dramatically in the coming decades. In model organisms, the process o...

  • DrugAge database of compounds that increase lifespan

    DrugAge database of compounds that increase lifespan

    Biomedical Sciences Liverpool August 24, 2015 Check with publisher

    We're starting a new database of drugs and compounds (including natural products) with anti-ageing properties that extend longevity in model organisms. The database will be called DrugAge, and although we have some data already, we are looking for da...

Listings
  • Drug Master Files and Quality Agreement Training Seminar 2018

    Drug Master Files and Quality Agreement Training Seminar 2018

    Drug Development Philadelphia (PA,PA) March 6, 2018 1495.00 Dollar US$

    Overview: This combined DMF (Drug Master Files) and Quality Agreement training will discuss the advantages for suppliers and drug product manufacturers in developing these arrangements together. Over time, there have been several misunderstandings be...

  • Label Promotion of Drugs and Medical Devices

    Label Promotion of Drugs and Medical Devices

    Training and Teaching Fremont (California) February 22, 2018 290.00 Dollar US$

    Overview: This session sets the context for the off-label promotion of medical products starting with early history and moving to the most recent history of FDA's decision on guidance documents. Why should you Attend: This class presents the latest F...

  • Discussion on Raw Material Methods and Specifications

    Discussion on Raw Material Methods and Specifications

    Medical Sciences Fremont (California) February 22, 2018 Check with publisher

    Overview: Based on knowledge of the active and inactive ingredient's function and role in the finished dosage form, Compendia methods and specifications are clearly accepted by third parties and regulatory agencies. Why should you Attend: The FDA has...

  • GMP for Phase I Investigational Drug Products 2018

    GMP for Phase I Investigational Drug Products 2018

    Training and Teaching Fremont (California) January 24, 2018 150.00 Dollar US$

    Overview: Phase I clinical trials are the first time that investigational new drugs are introduced into human subjects and, although it is very, very important for all drugs to be manufactured using GMPs, it is probably more important than at any oth...

  • FDA Guidelines for Pharmaceutical Industry | FDA Regulatory 2018

    FDA Guidelines for Pharmaceutical Industry | FDA Regulatory 2018

    Training and Teaching Chicago, IL ( Chicago, IL) January 19, 2018 1295.00 Dollar US$

    Course "FDA Penalties for Regulatory Non-Compliance in the Pharmaceuticals Industry - 2017 in Review" has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion. Overview: The FDA i...

  • Drug Products for Clinical Trials | FDA Approved Drugs List 2018

    Drug Products for Clinical Trials | FDA Approved Drugs List 2018

    Training and Teaching Boston, MA (Boston) January 19, 2018 1295.00 Dollar US$

    Course "Different requirements for Phase I Investigational Drug Products: which GMPs apply since most Phase I drugs are exempt from full GMP requirements and what IND data requirements are necessary as a result?" has been pre-approved by RAPS as elig...

  • Anti-TPBG (clone A1)-AcBut-calicheamicin ADC

    Anti-TPBG (clone A1)-AcBut-calicheamicin ADC

    Drug Development Shirley (New York) January 18, 2018 1.00 Dollar US$

    https://www.creative-biolabs.com/adc/target-tpbg-100.htm This ADC product is comprised of an anti-TPBG monoclonal antibody (clone A1) conjugated via an AcBut linker to calicheamicin. The calicheamicin is targeted to TPBG-positive cancers by immunerec...

  • Anti-TPBG (clone A1)-SMCC-DMA ADC

    Anti-TPBG (clone A1)-SMCC-DMA ADC

    Drug Development Shirley (New York) January 18, 2018 1.00 Dollar US$

    http://science-marketplace.org/services/drug-development_1/anti-tpbg-clone-a1-smcc-dma-adc_i3004 This ADC product is comprised of an anti-TPBG monoclonal antibody (clone A1) conjugated via a SMCC linker to DMA. The DMA is targeted to TPBG-positive ca...

  • Anti-FUT3 (clone hu3S193)-AcBut-CalichDMH ADC

    Anti-FUT3 (clone hu3S193)-AcBut-CalichDMH ADC

    Drug Development Shirley (New York) December 18, 2017 1.00 Dollar US$

    https://www.creative-biolabs.com/adc/target-fut3-48.htm This ADC product is comprised of an anti-FUT3 monoclonal antibody (clone hu3S193) conjugated via a AcBut linker to CalichDMH. The CalichDMH is targeted to certain cancers by immunerecognition an...

  • Anti-FOLR1-S-S-Dox ADC

    Anti-FOLR1-S-S-Dox ADC

    Drug Development Shirley (New York) December 15, 2017 1.00 Dollar US$

    https://www.creative-biolabs.com/adc/target-folr1-47.htm This ADC product is comprised of an anti-FOLR1 monoclonal antibody conjugated via a linker to Dox. The Dox is targeted to certain cancers by immunerecognition and delivered into cancer cells vi...

  • Anti-FOLR1 (clone M9346A)-sulfo-SPDB-DM4 ADC

    Anti-FOLR1 (clone M9346A)-sulfo-SPDB-DM4 ADC

    Drug Development Shirley (New York) December 15, 2017 1.00 Dollar US$

    https://www.creative-biolabs.com/adc/target-folr1-47.htm This ADC product is comprised of an anti-FOLR1 monoclonal antibody (clone M9346A)conjugated via a sulfo-SPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and del...

  • Anti-FOLR1 (M9346A)-SPDB-DM4 ADC

    Anti-FOLR1 (M9346A)-SPDB-DM4 ADC

    Drug Development Shirley (New York) December 15, 2017 1.00 Dollar US$

    https://www.creative-biolabs.com/adc/target-folh1-46.htm This ADC product is comprised of an anti-FOLR1 monoclonal antibody (M9346A) conjugated via a SPDB linker to DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into c...